Definitive Contract 75A50122C00061
Award Date
9/30/22
Potential Completion Date
9/29/32
Potential Value
$857M
Awardee
Mapp Biopharmaceutical, Inc.
Ultimate Awardee
Not listed
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
San Diego, CA 92121, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
2
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $38,243,034.02 cost-plus-fixed-fee contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Mapp Biopharmaceutical, Inc. for the development of medical countermeasures through planned clinical trials and outbreak preparedness. The contract is not set aside. The original solicitation was a Broad Agency Announcement from BARDA seeking proposals for advanced research and development of medical countermeasures against chemical, biological,...
This is a cost-plus-fixed-fee definitive contract awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) to Mapp Biopharmaceutical, Inc., a San Diego-based biotechnology company. The contract, which has a potential value of $7,486,450.79, is for an expanded access protocol for the drug ZMapp to treat viral hemorrhagic fevers like Ebola, Marburg, and Lassa. Mapp Biopharmaceutical is a prime contractor for ASPR, having...
This is a $30,920,844.79 cost-plus-fixed-fee contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Mapp Biopharmaceutical, Inc., a biotechnology company based in San Diego, California. The contract is for the development of an Expanded Access Protocol (EAP) for ZMapp, an antibody-based therapeutic for treating viral hemorrhagic fevers such as Ebola, Sudan, and Marburg. This contract is part of the U.S. government's efforts to prepare and respond to...
This is a cost-plus-fixed-fee contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Mapp Biopharmaceutical, Inc. for the development of Mapp's therapeutic intervention MBP091 as an immunotherapy for the treatment of Marburg virus infection. The contract has a ceiling value of $299,045,139.03 and a performance period ending on July 31, 2036. No set-aside was used for this award. The contract was awarded under a Broad Agency Announcement (BAA)...
This is a $149,747,956 definitive cost-no-fee contract awarded by the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) to the Albert B. Sabin Vaccine Institute, Inc. to advance the development of monovalent vaccines for the prevention of Marburg virus (MARV) and Sudan ebolavirus (SUDV) disease. The contract has an ultimate completion date of September 30, 2026 and was awarded on September 26, 2019. This effort is part of BARDA's...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense to Mapp Biopharmaceutical, Inc., a San Diego-based biotechnology company. The firm-fixed-price purchase order, with a potential value of $149,998.71, is for research and development efforts related to STTR Phase I work. Mapp Biopharmaceutical has extensive experience providing therapeutic interventions and medical...
This is a $30,559,760.00 cost-plus-fixed-fee delivery order awarded by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Emergent Manufacturing Operations Baltimore LLC, a for-profit manufacturer of medical countermeasures. The contract is for the development of the MAPP biopharmaceutical Viral Hemorrhagic Fever (VHF) Medical Countermeasure (MCM) platform. This work is being performed under the Centers for Innovation in...
This is a $1,403,362,669.10 cost-plus-fixed-fee contract awarded by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Emergent Product Development Gaithersburg Inc., a for-profit limited liability company manufacturing medical countermeasures and pharmaceuticals. The contract, which has a period of performance through September 29, 2026, is for the development of filovirus treatments. Emergent has received over $1.3...
This is a sole-source contract awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) to Ridgeback Biotherapeutics LP for the development and manufacturing of the monoclonal antibody treatment mAb114 for Ebola virus disease (EVD). The contract has a ceiling value of $159,990,035.88 and a period of performance through July 31, 2023. It was awarded on March 19, 2020 as a cost-plus-fixed-fee definitive contract. The...
This firm fixed-price contract, valued at $762,812,695, was awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS) to Emergent Product Development Gaithersburg Inc., a for-profit limited liability company. The contract is for the development of medical countermeasures (MCM) that can be deployed in the event of a filovirus outbreak, which is a crucial component of the U.S. government's outbreak response...